Studies gut microbes and body chemicals in obesity and muscle loss
Collects samples from adults to study gut microbes in obesity and muscle loss.
Plain-language title generated from the registry record
Registry title: Pilot Study of the Human Metagenome in Metabolic Diseases
Key facts
- Where
- Singapore, SingaporeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 99 years old?
Source: NCT06363253, who can take part
Where in Singapore
- Sengkang General HospitalSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sengkang General Hospital
- Trial code
- NCT06363253
- Record updated
- 15 May 2025
- Original description
This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.Read full original descriptionShow less
Understanding the Role of the Human Metagenome in Obesity, Metabolic Diseases, Chronic Inflammation, Sarcopenia and Sarcopenic Obesity - a Pilot Study
This is a cohort study to understand the role of the human metagenome, and associated metabolites, in health and in various diseased states, in particular obesity as well as sarcopenia.
Recruited participants will have their fecal, salivary, urine, serum, and in certain instances, mucosal samples taken, for metagenomic sequencing and metabolite testing.
We hope to uncover various differences and signatures in the metagenome and metabolome in various diseased states, with potential future therapeutic applications in personalised medicine.
Inclusion: Obese (BMI>27.5kg/m2); Sarcopenic patients, defined as 1) low handgrip strength (<26 for males; <18kg for females), AND/OR low gait speed (<0.8m/s) AND low muscle mass (<7.0kg/m2 for males; <5.7kg/m2 for females); Healthy subjects without sarcopenia, and not obese (BMI<27.5kg/m2).
Exclusion: No informed consent; Presence of intestinal stoma, hence inability to collect fecal samples.